NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary items found
Status Description Section
REDEtanercept Benepali® Musculoskeletal and joint diseases, Cytokine modulators, 10.01.03
REDEtanercept Benepali® Skin, Drugs affecting the immune response, 13.05.03
Searchiing the National BNF we found these items - Click button under Local to search local formulary or BNF to view on online BNF.
Local BNF Section
Etanercept Etanercept Musculoskeletal System, Arthritis, Immunosuppressants Tumor Necrosis Factor Alpha (TNF-A) Inhibitors
Etanercept Etanercept Skin, Inflammatory Skin Conditions, Eczema And Psoriasis, Immunosuppressants Tumor Necrosis Factor Alpha (TNF-A) Inhibitors
Selecting a button in the local column will search the local formulary again for the word on the button. Where the button is in outline no local match at drug name level was found.
Links found
NICE TA 715 Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
NICE TA103: Psoriasis - efalizumab and etanercept
NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab
NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab (NICE TA199)
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
NICE TA375:Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis
NICE TA455:Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
NICE TA455:Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people